Abstract: Complexes containing the anions of 5-benzoylamido-l,3,4-thiadiazole-2-sulfonamide and 5-(3-nitro-benzoylamido)-l,3,4-thiadiazole-2-sulfonamid as ligands, and V(IV); Cr(III); F(III); COO0; Ni(II); Cu(II) and Ag(I) were synthesized and characterized by standard procedures (elemental analysis; IR, electronic, and EPR spectroscopy; TG, magnetic and conductimetric measurements). The original sulfonamides and their metal complexes are strong inhibitors of two carbonic anhydrase (CA) isozymes, CA and II.
Introduction
1,3,4-Thiadiazol-2-sulfonamid derivatives such as acctazolamid 1, benzolamid 2 or chlorzolamid 3 arc clinically used pharmacological agents, which owe their biological activity to the inhibition of the zinc enzyme carbonic anhydras (CA, EC 4.2.1.1). -4 Since many isoforms of CA are presently known in higher vertebrates, and since the physiological function for some of them is rather unclear, novel types of sulfonamid -6' as well as non-sulfonamid CA inhibitors arc designed in order to select a series of compounds specific for the different CA isocnzymes, the final goal being the comprehension of the physiological functions of each of them and possibly their control. Among these, metal complexes of heterocyclic sulfonamidcs of type 1-3 exhibited valuable inhibitory properties against several CA isozymes. Since there is a net discrimination of sulfonamide inhibitors as well as their metal complexes towards the rapid type CA isozymes (such as CA II and CA IV) versus the low type ones (such as CA I and 235 III), our approach might lead to more specific inhibitors.
In this paper we report the preparation of metal complexes of two new sulfonamide CA inhibitors, i.e., 5obenzoylamino-l,3,4-thiadiazole-2-sulfonamide 4, and its 3onitrophenyl-analogue 5, which were recently reported by this group, and which possess good CA inhibitory properties. The V(IV), Cr(III), Fe(III), Co(II), Ni(II), Cu(II) and Ag(I) complexes containing the conjugate bases of the two sulfonamides 4 and 5 were obtained and characterized by standard procedures (elemental analysis, IR, electronic, and EPR spectroscopy; TG, magnetic and conductimetric measurements). The new complexes possess good inhibitory properties against the red cell isozymes CA and CA II, which are the predominant CAs is mammalian blood and secretory organs.
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Results and Discussion
The metal complexes containing the conjugate bases of sulfonamides 4 and 5 and transition metal ions are shown in Table I , together with their elemental analysis data.
The newly prepared compounds, 6-23, were also characterized by IR-, electronic and EPR spectroscopy, thermogravimetric (TG) and conductimetry. Some of these data are presented in Table II .
In the IR spectra of complexes 6-23, the major modifications, as compared to the spectra of the sulfonamides 4 and 5 from which they were prepared, concern the two vibrations of the sulfonamido moieties, shifted by 5-10 cm" (for the Sgy.metric vibration) and 5-15 cm" (for the asymmetric one), respectively, towards lower wavenumbers, indicating that the deprotonated sulfonamido moieties of the ligands interacts with the metal ions, as well as the shift of the C=N vibration in the spectra of the complexes with 5-45 cm "l towards lower wavenumbers (except for compounds 13 
NiO + CO2 + SO2 + N + H_O The first step is the one in which the two water molecules are lost (an exothermic process), as mentioned above. The anhydrous complex undergoes then a lost of benzaldehyde (step 2)at 245 C (endothermic process; weight loss, found: 34.1%; ealc. for two benzaldehyd molecules: 33.9 %), with formation of a highly unstable (unidentified) complex, which is further decomposed. Finally, the last step involves the complete oxidation of this last complex to NiO and gaseous compounds (step 3). 
Metal-Based Drugs
Conductimetric data (Table II) showed the complexes 10 and 18 to behave as 1:1 electrolytes, the complexes 13 and 22 as 2:1 electrolytes, and all the other new complexes, as well as the sulfonamides from which they were prepared, as non-electrolytes.
The conjugate bases of the two sulfonamides 4 and 5, used as ligands for the preparation of the complexes, probably act mono-or bidentately, as previously shown for the complexes containing main group metal ions. When acting as monodentate ligands, the donor system is constituted by the sulfonamido nitrogen atom, whereas when bidentate, by the endocyclic N-3 and the sulfonamidic nitrogen. It is quite probable that the two ligands have the same behavior in their complexes with transition metal ions, reported here. Monodentate behavior is present only for the two Cu(II) complexes 13 and 22, whereas in all other compounds the ligands act bidentately. This behavior is supported by the spectroscopic, analytic and TG data presented above.
In Table III diffuse reflectance electronic spectra, magnetic susceptibility data at room temperature and the proposed geometries for the metal ions in the new complexes are presented.
Thus, the two vanady_l derivatives, 6 and 15, show an electronic spectrum characteristic of V(IV) in square pyramidal geometry, which is confirmed by the magnetic susceptibility data. 9 The Cr(III) and Table IV . From the inhibition data of Table IV , it is obvious that the new complexes act as strong inhibitors of both isoymes, comparably with the standard (and very potent) CA inhibitor benzolamide, and much stronger ones than the other clinically used compound, acetazolamide. No major differences were observed between the two sulfonamides 4 and 5, except for the fact that the nitro-substituted compound 5 is slightly more active than 4 (a trend generally also manifested by the complexes containing the conjugate bases of these sulfonamides). This may be accounted on the acidification of the sulfonamido protons by the nitro moiety. TM The less efficient inhibitors were the V(IV), Cr(III) (it should be noted that compounds 7 and 16 are the first chromium complexes of sulfonamides ever reported) and Ni(II) derivatives, whereas cations such as Fe(III), Co(II), Cu(II) and Ag(I) led to the most active inhibitors. Great differences between the two isozymes were also revealed, with CA II being much more susceptible to inhibition by sulfonamides and metal complexes, as compared to CA I. Although CA I is a relatively sulfonamide resistant enzyme, 2'3 it should be noted that several complexes reported here, such as 9, 14, 19, and 21, showed very good inhibition properties, although they also inhibited CA II quite potently, so that isozyme-specificity was not achieved yet with this class of inhibitors.
